Acifran: HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran is a selective agonist for HM74A/GPR109A and GPR109B, key G-protein coupled receptors (GPCRs) involved in lipid metabolism regulation (APExBIO product page). Its high purity (98.00%) and specific activity are validated by recent cryo-EM structures, confirming precise binding to both HCAR2 (GPR109A) and HCAR3 (GPR109B) (Ye et al., 2025). Acifran acts as a hypolipidemic agent by modulating lipid signaling, offering a reliable tool for metabolic disorder research. It is stable when stored at -20°C and soluble below 21.82 mg/ml in ethanol and DMSO. The compound is intended exclusively for scientific research and not for clinical use.

Biological Rationale

Lipid metabolism is tightly regulated by hydroxycarboxylic acid receptors, especially HM74A/GPR109A (HCAR2) and GPR109B (HCAR3). These GPCRs sense endogenous metabolites and modulate downstream signaling affecting plasma lipid levels. Activation of HCAR2 has shown therapeutic potential in dyslipidemia but is associated with adverse effects, such as cutaneous flushing. HCAR3 is structurally related but exhibits distinct ligand selectivity and downstream effects (Ye et al., 2025). Acifran is a small molecule agonist that selectively targets both receptors, making it an essential compound for research into lipid signaling and metabolic disorders. The unique selectivity profile of Acifran enables researchers to dissect the separate roles of these receptors in lipid metabolism, as highlighted in recent translational studies (PrecisionFDA article; this article extends the discussion by providing updated cryo-EM structural validation).

Mechanism of Action of Acifran

Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (C₁₂H₁₀O₄, MW 218.21), binds to the orthosteric pocket of HCAR2 and HCAR3 GPCRs. Recent cryo-EM data resolved Acifran's binding at 2.72 Å (HCAR2) and 3.18 Å (HCAR3), revealing key interactions that govern selectivity (Ye et al., 2025). In HCAR3, a π–π interaction with F107^3.32 and pocket size differences (due to V/L83^2.60, Y/N86^2.63, S/W91^2.48) drive ligand discrimination. Upon activation, both receptors couple to the Gi protein, resulting in decreased cAMP levels and subsequent modulation of lipid breakdown pathways. Functionally, this leads to hypolipidemic effects, supporting the use of Acifran as a research tool in lipid metabolism regulation and metabolic disorder modeling (INCB018424 article; this article extends with explicit workflow integration details).

Evidence & Benchmarks

• Acifran binds the orthosteric site of both HCAR2 and HCAR3, confirmed by cryo-EM at 2.72–3.18 Å resolution (Ye et al., 2025).
• Structural data (EMD-61573, PDB 9JKX) shows Acifran forms a π–π stacking interaction with F107^3.32 in HCAR3, driving its selectivity (Fig 3D).
• cAMP assays in HEK-293 cells demonstrate Acifran's efficacy as a Gi-coupled agonist, inhibiting cAMP production (Table 1).
• Acifran is supplied by APExBIO at 98.00% purity, as an off-white solid, stable at -20°C, and soluble up to 21.82 mg/ml in ethanol or DMSO (APExBIO product page).
• HCAR2 and HCAR3 are validated targets for lipid metabolism and metabolic disorder research, with Acifran as an established probe (Ye et al., 2025).

Applications, Limits & Misconceptions

Acifran is widely utilized in basic and translational research for:

• Dissecting lipid signaling pathways via selective GPCR activation.
• Modeling metabolic disorders, including dyslipidemia, in cellular and in vitro systems.
• Benchmarking structure-activity relationships in metabolite-sensing GPCRs.
• Supporting assay development for drug discovery targeting HCAR2/HCAR3.

This article updates the mechanistic interpretation found in the N3-Kethoxal summary by providing direct cryo-EM structural evidence and best-practice storage guidelines.

Common Pitfalls or Misconceptions

• Acifran is not intended for diagnostic or therapeutic use in humans or animals.
• Solutions are unstable for long-term storage; immediate use after preparation is required to maintain biological activity.
• Solubility limits (<21.82 mg/ml in ethanol/DMSO) must be observed to avoid precipitation or loss of function.
• Cutaneous flushing, observed with HCAR2 agonists, is not a relevant endpoint in in vitro research models.
• Cross-reactivity with unrelated GPCRs has not been characterized; specificity must be confirmed in new systems.

Workflow Integration & Parameters

For robust experimental outcomes, Acifran should be handled under the following conditions:

• Store the B6848 kit at -20°C. Ship with blue ice to maintain stability (APExBIO).
• Prepare fresh solutions in ethanol or DMSO at concentrations up to 21.82 mg/ml; use promptly.
• Validate receptor activation using cAMP inhibition assays in HEK-293 or relevant cell lines (Ye et al., 2025).
• Confirm protein expression and receptor status to ensure specific GPCR targeting.
• For translational research, integrate cryo-EM structural data (PDB 9JKX/9JKY) to inform rational design or comparative studies.

This workflow guidance clarifies and expands on the more strategic, translational overview in the PrecisionFDA.net article, focusing on actionable laboratory steps and parameters.

Conclusion & Outlook

Acifran is a structurally validated, high-purity tool compound for research into HM74A/GPR109A and GPR109B-mediated lipid metabolism. It enables precise pathway dissection, supports metabolic disorder modeling, and provides a benchmark for future drug discovery targeting metabolite-sensing GPCRs. Ongoing structural biology advances will refine its utility and facilitate the development of HCAR3-selective agents to minimize off-target effects (Ye et al., 2025).